76 related articles for article (PubMed ID: 19930022)
21. Modelling the hepatitis B vaccination programme in prisons.
Sutton AJ; Gay NJ; Edmunds WJ; Andrews NJ; Hope VD; Gilbert RL; Piper M; Gill ON
Epidemiol Infect; 2006 Apr; 134(2):231-42. PubMed ID: 16490125
[TBL] [Abstract][Full Text] [Related]
22. Validity of injecting drug users' self report of hepatitis A, B, and C.
Schlicting EG; Johnson ME; Brems C; Wells RS; Fisher DG; Reynolds G
Clin Lab Sci; 2003; 16(2):99-106. PubMed ID: 12757189
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B immunisation in travellers: poor risk perception and inadequate protection.
Zuckerman JN; Hoet B
Travel Med Infect Dis; 2008 Sep; 6(5):315-20. PubMed ID: 18760256
[TBL] [Abstract][Full Text] [Related]
24. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
25. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
27. Molecular epidemiology of hepatitis B virus infections in Denmark.
Fisker N; Pedersen C; Lange M; Nguyen NT; Nguyen KT; Georgsen J; Christensen PB
J Clin Virol; 2004 Sep; 31(1):46-52. PubMed ID: 15288613
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B immunity in a population of drug and alcohol users.
Polizzotto MN; Whelan G
Drug Alcohol Rev; 2007 Jul; 26(4):417-9. PubMed ID: 17564878
[TBL] [Abstract][Full Text] [Related]
29. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.
Mele A; Tosti ME; Mariano A; Pizzuti R; Ferro A; Borrini B; Zotti C; Lopalco P; Curtale F; Balocchini E; Spada E;
Clin Infect Dis; 2008 Mar; 46(6):868-75. PubMed ID: 18269332
[TBL] [Abstract][Full Text] [Related]
30. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population.
Hwang LY; Kramer JR; Troisi C; Bull L; Grimes CZ; Lyerla R; Alter MJ
Hepatology; 2006 Aug; 44(2):341-51. PubMed ID: 16871571
[TBL] [Abstract][Full Text] [Related]
31. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus infection risk factors and immunity among sexually transmitted disease clinic clients.
Trepka MJ; Weisbord JS; Zhang G; Brewer T
Sex Transm Dis; 2003 Dec; 30(12):914-8. PubMed ID: 14646641
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus infection among street youths in Montreal.
Roy E; Haley N; Lemire N; Boivin JF; Leclerc P; Vincelette J
CMAJ; 1999 Sep; 161(6):689-93. PubMed ID: 10513274
[TBL] [Abstract][Full Text] [Related]
34. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness.
de la Hoz F; Perez L; de Neira M; Hall AJ
Int J Infect Dis; 2008 Mar; 12(2):183-9. PubMed ID: 17913535
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B and C infection among drug abusers in Nepal.
Shrestha SM; Shrestha DM; Gafney TE; Maharjan KG; Tsuda F; Okamoto H
Trop Gastroenterol; 1996; 17(4):212-3. PubMed ID: 9094859
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B vaccination and injecting drug users.
Budd J; Robertson R; Elton R
Br J Gen Pract; 2004 Jun; 54(503):444-7. PubMed ID: 15186567
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users.
Lin CL; Liu CJ; Chen PJ; Lai MY; Chen DS; Kao JH
J Med Virol; 2007 Nov; 79(11):1674-8. PubMed ID: 17854041
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of hepatitis B virus markers among intravenous drug abusers in Stockholm: impact of heterosexual transmission.
Struve J; Käll K; Stendahl P; Scalia-Tomba G; Giesecke J; Weiland O
Scand J Infect Dis; 1993; 25(1):8-13. PubMed ID: 8460353
[TBL] [Abstract][Full Text] [Related]
39. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City.
Amesty S; Ompad DC; Galea S; Fuller CM; Wu Y; Koblin B; Vlahov D
J Community Health; 2008 Jun; 33(3):139-48. PubMed ID: 18185987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
